Plasma carboxypeptidase B inhibitors

A compound of formula (I):

• wherein:
• R1 is hydrogen;
• R2 is —SH, —S—C(O)—R8, —P(O)(OR5)2, —P(O)(OR5)R6, —P(O)(OR5)—R7—N(R6)2, —P(O)(OR5)—R7—C(O)—R8, —P(O)(OR5)—R7—N(R5)—C(O)OR8, or —P(O)(OR5)—R7—N(R5)—C(S)—N(R6)2;
• R3 is tetrazole, —C(O)OR6, or —C(O)O—R7—OC(O)R5;
• R4 is phenyl substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, haloalkoxy, mercapto, alkylthio, phenyl, cycloalkyl, nitro, cyano, —OR6, —N(R6)2, —R7—N(R6)2, —N(R6)—C(O)OR8, —R7—N(R6)—C(O)OR8, —N(R6)—C(O)—R6, —R7—N(R6)—C(O)—R6, —C(O)—N(R6)2, —C(O)—R7—N(R6)2, —N(R5)—C(NR5)—N(R5)2, —N(R5)—C(O)—N(R6)2 and —N(R5)—C(O)—R7—N(R62);
• each R5 is independently hydrogen, alkyl or aralkyl;
• each R6 is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl or aralkenyl;
• each R7 is independently cycloalkylene (optionally substituted by alkyl), a straight or branched alkylene chain (optionally substituted by hydroxy, mercapto, alkylthio, aryl, cycloalkyl, —N(R6)2, —C(O)OR6, or —C(O)N(R6)2), or a straight or branched alkenylene chain (optionally substituted by hydroxy, mercapto, alkylthio, aryl, cycloalkyl, —N(R6)2, —C(O)OR6, or —C(O)N(R6)2);
• and
• each R8 is independently alkyl, alkenyl, aryl, aralkyl or aralkenyl;
• provided that when R3 is —C(O)OH or when R4 is a substituted phenyl, R2 can not be —P(O)(OR5)—R7—N(H)—C(O)OR8;
• as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;
• or a pharmaceutically acceptable salt thereof.